Answers are grounded in this paper and cite their sources.
AIM: Neonates admitted to neonatal intensive care units (NICUs) are frequently exposed to central nervous system (CNS) depressant medications, increasing the risk of potential drug-drug interactions (DDIs). However, evidence on the clinical outcomes associated with these interactions remains limited. This study evaluated the association between DDIs with the potential for CNS depression and clinical outcomes in neonates admitted to a NICU. METHODS: This prospective observational cohort study included 600 neonates admitted to a NICU in Brazil. Pharmacotherapy was monitored daily, and DDIs with the potential for CNS depression were identified using the UpToDate® database. Clinical outcomes associated with specific drug combinations were analysed. RESULTS: A total of 89 neonates (14.8%) were exposed to at least one DDI with the potential for CNS depression. These interactions were associated with a higher occurrence of hypoactivity, reduced peripheral oxygen saturation and mortality. The fentanyl/phenobarbital combination showed the most consistent risk profile, being associated with all evaluated outcomes. Interactions involving magnesium sulphate were associated with reduced oxygen saturation, while fentanyl/fluconazole was associated with increased mortality. CONCLUSION: DDIs with the potential for CNS depression were associated with clinically relevant adverse outcomes in neonates. The findings highlight fentanyl/phenobarbital as the combination of greatest clinical concern and suggest that oxygen saturation may be a useful marker for monitoring CNS-related DDIs in neonatal intensive care.
No takes yet. Share an insight, caveat, or question.
Marques et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: